You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和鉑醫藥(02142.HK)於2022 ASCO年會上發布HBM4003研究進展
阿思達克 06-01 12:24
和鉑醫藥(02142.HK)表示,已於2022 ASCO年會上,發布產品HBM4003單藥療法及與抗PD-1抗體聯合療法的研究進展,其中用於評估HBM4003治療晚期黑色素瘤及其他實體瘤患者的I期開放標籤研究,結果顯示HBM4003與特瑞普利單抗聯用,在晚期黑色素瘤中顯示出良好的抗腫瘤活性且安全可耐受。 公司表示,隨著進一步實施其全球創新發展策略,將繼續全力推進HBM4003的全球臨床開發項目,相信該產品有望引領下一代多實體瘤免疫腫瘤療法的發展。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account